PTC Therapeutics, Inc. (NASDAQ:PTCT) Q3 2024 Earnings Call Transcript
Q3 2024 Earnings Call Transcript November 7, 2024 PTC Therapeutics, Inc. beats earnings expectations. Reported EPS is $-1.39, ...
PTC Therapeutics: Balancing Growth Opportunities and Risks with Hold Rating
Analyst Jeffrey Hung of Morgan Stanley maintained a Hold rating on PTC Therapeutics (PTCT – Research Report), retaining the price target ...
Business Insider4d
PTC Therapeutics: Strong Q3 Performance Amid Market and Regulatory Challenges, Holds Rating Amid Mixed Future Outlook
Begin your TipRanks Premium journey today. PTC Therapeutics (PTCT) Company Description: PTC Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and commercialization of ...
Zacks.com on MSN4d
PTC Therapeutics (PTCT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
PTC Therapeutics (PTCT) reported $196.79 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 0.1%. EPS of -$1.39 for the same period compares to -$1.76 a ...
PTC Therapeutics: Q3 Earnings Snapshot
The biopharmaceutical company posted revenue of $196.8 million in the period, also beating Street forecasts. Five analysts surveyed by Zacks expected $173.5 million. PTC Therapeutics expects full-year ...
PTC Inc.: Fiscal Q4 Earnings Snapshot
PTC Inc. (PTC) on Wednesday reported fiscal fourth-quarter earnings of $126.5 million. The Boston-based company said it had net income of $1.04 per share.